Latest Lung cancer staging Stories
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) has demonstrated that an available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods.
Using two cell surface markers found to be highly expressed in breast cancer lymph node metastases, researchers at Moffitt Cancer Center, working with colleagues at other institutions, have developed targeted, fluorescent molecular imaging probes that can non-invasively detect breast cancer lymph node metastases.
Patients with Merkel Cell Carcinoma who underwent a procedure called sentinel lymph node biopsy (SNLB) had a lower risk of cancer recurrence after two years.
The number of lymph nodes evaluated for colon cancer has risen significantly over the past two decades.
During the past two decades there has been a significant increase in the percentage of patients who have a high number of lymph nodes evaluated during colon cancer operations, but this improvement is not associated with an increase in the overall proportion of colon cancers that are node positive.
The relevance of positron emission tomography (PET) alone or in combination with computed tomography (CT) in patients with malignant melanoma cannot be currently assessed due to a lack of meaningful studies.
Patients who underwent endoscopic testing prior to surgery for lung cancer had significantly better quality of life at the end of the staging process, with no significant difference in costs between the two strategies.
In the largest reported series yet to compare transcervical extended mediastinal lymphadenectomy (TEMLA) with endoscopic and surgical primary staging and restaging of non-small cell lung cancer (NSCLC), TEMLA showed a significantly higher diagnostic yield.
VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today announced that it will present data showing how adjunctive use of its LuCEDâ„¢ test can improve the utility of low dose x-ray computed tomography (CT) screening for the early detection of lung cancer in high risk individuals.
- Growing in low tufty patches.